Anzeige
Mehr »
Donnerstag, 12.02.2026 - Börsentäglich über 12.000 News
Top-Ergebnisse: 1,75 g/t Gold über 30,4 Meter + massives Tagebau-Potenzial
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A41H9X | ISIN: NL0015002K83 | Ticker-Symbol: JP71
Tradegate
12.02.26 | 11:42
14,580 Euro
-0,44 % -0,064
Branche
Dienstleistungen
Aktienmarkt
AMX
1-Jahres-Chart
HAVAS NV Chart 1 Jahr
5-Tage-Chart
HAVAS NV 5-Tage-Chart
RealtimeGeldBriefZeit
14,57014,59012:07
14,57014,59012:07
PR Newswire
345 Leser
Artikel bewerten:
(2)

Havas Health Network Announces Two Senior Strategic Appointments

Christina Stoddard appointed EVP, Head of Strategy, for global flagship clients, and Ayesha Walawalkar named CSO of Havas Lynx UK

NEW YORK, Sept. 9, 2025 /PRNewswire/ -- Havas Health Network today announced the appointment of two senior strategic leaders: Christina Stoddard as Executive Vice President, Head of Strategy, where she will lead strategy for global flagship clients, and Ayesha Walawalkar as Chief Strategy Officer for Havas Lynx UK. These hires reflect the network's continued investment in integrated, audience-first thinking to power culturally resonant brand strategy across health and wellness.

Havas Health Logo

"Christina and Ayesha represent the caliber of strategic leadership that defines the future of Havas Health Network, and we're thrilled to welcome them to our leadership team," said Brian Robinson, Global Chief Strategy Officer and Head of Growth, Havas Health Network. "As our network expands and the industry evolves, we're investing in leaders who understand the complexities of health, culture, and data, and can shape that knowledge into market-transforming work."

Christina Stoddard has been appointed EVP, Head of Strategy focusing on global integrated client work, leading strategy across all audiences, including HCP, patient, and consumer. Stoddard brings a rare combination of consumer and health experience, having led strategic work for global brands including Milk, TRESemmé, and Snickers, as well as three Super Bowl campaigns. Most recently, she served as Head of Strategy at 21Grams, where she helped drive the agency's rapid growth, particularly in the rare disease space. A recognized leader in healthcare marketing, she was named to MM+M's 40 Under 40 for her industry impact.

Over the course of her career, Stoddard has built a reputation for blending creativity with business rigor, and for pushing brands to connect with audiences in more human, more meaningful ways. She joins the leadership team and will work in close collaboration with cross-disciplinary teams to deepen audience insight and accelerate innovation across the business.

Ayesha Walawalkar joins as Chief Strategy Officer for Havas Lynx UK, where she will work alongside senior leadership to define and drive the next chapter of strategic growth. With more than 30 years of experience, she has led global brand strategies across both health and consumer sectors. Prior to Havas, she served as CSO at MullenLowe Global, where she led strategy for clients including Unilever, Kimberly-Clark, and Bayer Consumer Health.

Her work has received accolades from Cannes Lions, D&AD, Clio, Effie, and WARC. She has also been a longtime champion of equity and inclusion, most notably through IPG's "Invisible Powerhouse" initiative, which helped shape global ageism guidance for the Unstereotype Alliance.

Both leaders will join the Havas Health Network Global Strategy Leadership Team, where they will help shape the network's next evolution of strategic vision, rooted in integrated thinking across audiences, categories, and cultures.

ABOUT HAVAS HEALTH NETWORK
Havas Health Network unites Havas Life, Havas Lynx, and Jacques, all wholly owned health and communications networks, with the consumer health businesses and practices of Havas Creative Network. The network's approach is centered around making a meaningful difference and has the talent, tenacity, and technology that health companies, brands, and people need to thrive in today's world. For more information, visit www.HavasHealth.com

Logo - https://mma.prnewswire.com/media/2763952/Havas_Health_Network_Havas_Health_Network_Announces_Two_Senior_S.jpg

Cision View original content:https://www.prnewswire.co.uk/news-releases/havas-health-network-announces-two-senior-strategic-appointments-302547888.html

© 2025 PR Newswire
Favoritenwechsel
Das Börsenjahr 2026 ist für viele Anleger ernüchternd gestartet. Tech-Werte straucheln, der Nasdaq 100 tritt auf der Stelle und ausgerechnet alte Favoriten wie Microsoft und SAP rutschen zweistellig ab. KI ist plötzlich kein Rückenwind mehr, sondern ein Belastungsfaktor, weil Investoren beginnen, die finanzielle Nachhaltigkeit zu hinterfragen.

Gleichzeitig vollzieht sich an der Wall Street ein lautloser Favoritenwechsel. Während viele auf Wachstum setzen, feiern Value-Titel mit verlässlichen Cashflows ihr Comeback: Telekommunikation, Industrie, Energie, Pharma – die „Cashmaschinen“ der Realwirtschaft verdrängen hoch bewertete Hoffnungsträger.

In unserem aktuellen Spezialreport stellen wir fünf Aktien vor, die genau in dieses neue Marktbild passen: solide, günstig bewertet und mit attraktiver Dividende. Werte, die nicht nur laufende Erträge liefern, sondern auch bei Marktkorrekturen Sicherheit bieten.

Jetzt den kostenlosen Report sichern – bevor der Value-Zug 2026 endgültig abfährt!

Dieses exklusive PDF ist nur für kurze Zeit gratis verfügbar.
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.